Tesamorelin — 2 mg

Tesamorelin is a modified form of the 44-amino-acid growth-hormone-releasing hormone. By activating pituitary GHRH receptors, it increases endogenous growth-hormone output and downstream IGF-1 signaling. Umbrella identifies Egrifta and TH9507 as related names and emphasizes the compound’s connection with abdominal-fat research. Its endocrine mechanism differs from the appetite and incretin pathways targeted by semaglutide or tirzepatide.

Randomized studies in people with HIV and excess abdominal adiposity reported reductions in visceral fat and modest reductions in liver fat. Another trial involving HIV-associated fatty liver found a larger decline in hepatic fat fraction with tesamorelin than placebo and called for further work on long-term liver outcomes. These studies underpin descriptions centered on visceral adiposity, ectopic fat, and GH-axis physiology. They are not equivalent to demonstrating broad weight loss across all populations. The distinction between internal abdominal fat, liver fat, and total body weight is therefore important in a research description. Umbrella’s laboratory material is also separate from the pharmaceutical product used in clinical care.